Evidence map›Paper›PMID 29375856›Full record

ArticleClinical case reports2018

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Ahmad Alhuraiji, Kiran Naqvi, Yang O Huh, Coty Ho, Srdan Verstovsek, Prithviraj Bose

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Unraveling the role ofHemaSphere · 2026
    Review
  2. Review
  3. A Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Coexistence of theTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ahmad AlhuraijiDepartment of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.ORCID 0000-0002-4669-0233
Kiran NaqviDepartment of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Yang O HuhDepartment of Hematopathology University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Coty HoOklahoma Cancer Specialists and Research Institute Tulsa 74133 Oklahoma.
Srdan VerstovsekDepartment of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Prithviraj BoseDepartment of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
The University of Texas MD Anderson Cancer Center · USOklahoma Cancer Specialists and Research Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Philadelphia-negative (Ph

Indexed as

Acute lymphoblastic leukemiaJAK2 V617F mutationlenalidomidemyeloproliferative neoplasm

Identifiers

PMID29375856
PMCPMC5771935
OpenAlexW2775539634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.